@lapasqualotto's GHK-Cu peptide claims, fact-checked

What did @lapasqualotto actually say?

Honestly, this is a tough one to fact-check cleanly. The transcript provided is largely incoherent, a stream of disconnected phrases that don't correspond to any coherent medical claims about GHK-Cu. What we can work with is the caption, which claims GHK-Cu is a natural molecule that declines with age and in autoimmune disease, and that it can "reduce chronic inflammation" by inhibiting cytokines. Those are the claims worth examining. The video targets people with rheumatoid arthritis and polymyositis, conditions serious enough that vague peptide promises deserve scrutiny.

The caption frames GHK-Cu as something you can "reactivate," which is a marketing framing, not a clinical one. It implies a simple intervention for complex immune dysfunction. That framing should raise your eyebrows before you even look at the data.

Does the science back this up?

Partially, and with significant caveats. GHK-Cu does have legitimate research behind it, mostly in vitro and animal models, with very limited human trial data. The anti-inflammatory claims are not invented, but they are overstated for a clinical audience.

Pickart and Margolina (2018, Symmetry) documented GHK-Cu's role in modulating gene expression related to inflammation, including downregulation of pro-inflammatory cytokines like TNF-alpha and IL-6 in laboratory settings. That part is real. Gorouhi and Maibach (2009, International Journal of Cosmetic Science) reviewed GHK-Cu's tissue repair properties, showing wound healing effects in controlled studies. These are not nothing.

However, a 2023 review in Biomolecules found that most GHK-Cu studies with compelling results are conducted in cell cultures or rodents. Translation to human autoimmune disease, specifically conditions like polymyositis or rheumatoid arthritis, has not been demonstrated in randomized controlled trials. Claiming this peptide addresses those conditions crosses well past what the evidence supports.

What did they get wrong (or right)?

Right: GHK-Cu is indeed a naturally occurring tripeptide found in human plasma, and concentrations do decline with age. That is documented. Its presence in biological systems and its role in copper transport are not disputed. Pickart (1973, Nature) first identified it, so the foundational biology is solid.

Wrong: Framing GHK-Cu as a solution for autoimmune conditions like rheumatoid arthritis and polymyositis is a significant overreach. These are serious, often life-threatening diseases managed with immunosuppressants, biologics, and careful clinical monitoring. Polymyositis in particular can cause respiratory failure. Presenting a peptide with limited human data as something that can address these conditions without medical supervision is irresponsible, regardless of how promising the preclinical data looks.

Also wrong: The caption implies you can simply "reactivate" declining GHK-Cu levels as if that is a straightforward clinical option. The delivery mechanisms, dosing, bioavailability of exogenous GHK-Cu, and safety in immunocompromised populations remain poorly characterized in humans.

What should you actually know?

GHK-Cu is one of the more scientifically grounded peptides discussed in wellness communities. It is not pure fiction. But "more grounded than most" is a low bar, and it does not mean ready for prime time in serious autoimmune disease management.

If you have rheumatoid arthritis or polymyositis, your treatment decisions should involve a rheumatologist, not an Instagram caption. Peptide therapies like GHK-Cu may eventually earn a role in integrative protocols, but that requires human clinical trials that largely do not yet exist for these indications. A 2022 analysis in Frontiers in Aging found GHK-Cu promising for longevity-adjacent applications, but explicitly noted the gap between preclinical excitement and clinical validation.

Regulated telehealth platforms can evaluate whether peptide therapies like GHK-Cu might be appropriate for a specific patient, with proper intake, history, and clinical oversight. That is a very different thing from a social media video targeting people with serious autoimmune diagnoses and implying a peptide can reduce their suffering without qualification.